Entry into new markets
€70.1mn
Equity investment
€42mn
Revenues 2018
180
Employees 2018

KEY FACTS AT A GLANCE

  • Internationalisation of the business and optimisation of production processes
  • Expansion of manufacturing capacities and sales organisation
  • Strong market growth; revenues expected to be above previous year’s level

POLYTECH HEALTH & AESTHETICS GMBH

Investment by
DBAG FUND VI

€70.1MN

DBAG'S INTEREST

€13.3mn

MANAGEMENT BUYOUT
Shareholders:
DBAG FUND VI

78.9%

EQUITY SHARE BELONGING TO DBAG

15.0%

other shareholders

21.1%

First invested

OCTOBER 2016

REVENUES in €mn

 

31

 

2016

 

36

 

2017

 

42

 

2018

As of 31 March 2019

30

percent

average annual revenue growth between 2013 and 2017

We help Polytech to focus squarely on further developing the implants for medical use and to highlight its excellent “Made in Germany” seal of quality. The fact that we were able to find a solution to the future of this family-owned company by means of a management buyout is once again evidence of the high esteem in which we are held by German SMEs.

TOM ALZIN
MANAGING DIRECTOR

PROFILE

Polytech is a leading player in Europe in the development and production of silicone implants and is the sole German manufacturer of such products. The company specialises in breast implants used in reconstructive surgery after illness and in aesthetic plastic surgery.

The company has grown strongly in recent years. This expansion is based on production (under clean-room conditions) in Germany, which conforms to the highest quality standards, and the company’s innovative capacity. Polytech has developed surface textures for its products that lead to a clear reduction in the rate of complications.

POTENTIAL FOR DEVELOPMENT

In view of the very positive response to implants “Made in Germany”, Polytech has considerably expanded its sales activities. At the moment, the company generates around 40 percent of its revenues in Germany and in other western European countries. However, its implants are increasingly being distributed worldwide, currently in over 60 countries. Polytech serves a growth market that is expected to develop worldwide at an annual rate of around six percent in the next few years. Growth is being driven by a number of factors including rising prosperity and demographic change in industrialised countries.

FINANCIAL YEAR 2018

Polytech has continued along its path with sustained growth momentum since the start of the investment; the company also expects revenues to exceed the previous year’s level in the 2018 financial year. Polytech and G&G Biotechnology Ltd. merged in June 2018. G&G has developed the world’s first lightweight breast implant; the company’s products are used in over 30 countries in reconstructive and plastic surgery.

OUTLOOK AND OBJECTIVES

The merger with G&G is intended to enable Polytech to further expand its leading market position in Europe and widen the scope of its international activities. In order to be able to meet the rising level of demand in the future, the company is also working to further expand its capacities. At the same time, a new surface coating for implants was developed in cooperation with a partner company. It is now being tested in clinical studies.

Responsible team member

Tom Alzin
Tom Alzin

Managing Director

Tom Alzin
Name:
Tom Alzin
Telephone:
+49 69 95787-219
E-Mail:

Tom Alzin

Managing Director

Tom Alzin joined Deutsche Beteiligungs AG in 2004 and became a Managing Director in 2011.

He holds a degree in Business Administration from the HEC Lausanne, and also studied at the London School of Economics and Political Science.

Tom Alzin has 14 years of experience in private equity. During that time, he gained a wealth of knowledge, particularly in the mechanical and plant engineering and in the services sector. Tom Alzin was involved in numerous acquisitions and realisations and also in the IPO of Homag. The realisations of Homag and Spheros, subsequent to their very successful development, are two of his most successful transactions. Tom Alzin also led the investment process in FDG, Pfaudler, Schülerhilfe, Telio, Polytech, duagon and Kraft & Bauer and sits on the advisory councils of the companies, which are still part of the DBAG portfolio.

Current portfolio companies

Telio Management GmbH Polytech Health & Aesthetics GmbH Pfaudler International S.à r.l.

Former portfolio companies

Tom Alzin

Managing Director

+49 69 95787-219
tom.alzin(at)dbag.de